Surrozen, Inc. (NASDAQ:SRZN) Stock Has Average Target Price of $45.00 According to Brokerages

Surrozen, Inc. (NASDAQ:SRZN) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $45.00.

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Friday, July 17th. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating and set a $44.00 target price on shares of Surrozen in a research report on Monday, August 10th. Finally, William Blair assumed coverage on Surrozen in a research note on Thursday, August 20th. They set an “outperform” rating and a $51.00 target price on the stock.

Surrozen Stock Up 108.4%

Shares of SRZN opened at $33.68 on Friday. The business has a fifty day moving average of $21.74 and a 200 day moving average of $24.88. The company has a market cap of $391.02 million, a PE ratio of -0.83 and a beta of 0.56. Surrozen has a 52-week low of $11.39 and a 52-week high of $35.86.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The firm had revenue of $5.00 million for the quarter, compared to the consensus estimate of $0.47 million. As a group, research analysts anticipate that Surrozen will post -1.01 earnings per share for the current fiscal year.

Insider Transactions at Surrozen

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the company’s stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the transaction, the insider owned 574,047 shares of the company’s stock, valued at $12,198,498.75. This represents a 36.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.74% of the stock is currently owned by insiders.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently made changes to their positions in the business. Spruce Street Capital LP bought a new position in shares of Surrozen in the fourth quarter worth about $9,764,000. 5AM Venture Management LLC grew its stake in Surrozen by 25.0% in the 4th quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock worth $8,758,000 after acquiring an additional 77,500 shares in the last quarter. Perceptive Advisors LLC bought a new position in Surrozen in the 1st quarter worth about $6,682,000. Empery Asset Management LP purchased a new position in shares of Surrozen during the fourth quarter worth approximately $2,350,000. Finally, Eversept Partners LP raised its stake in shares of Surrozen by 23.8% during the fourth quarter. Eversept Partners LP now owns 95,286 shares of the company’s stock valued at $2,153,000 after acquiring an additional 18,289 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body.

The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression.